首页|甲状腺癌血浆循环DNA中SOX17基因甲基化与患者病情及预后的关系

甲状腺癌血浆循环DNA中SOX17基因甲基化与患者病情及预后的关系

扫码查看
原文链接
  • 万方数据
  • 维普
目的:探讨乳头状甲状腺癌(PTC)血浆循环 DNA 中 Y 染色体相关高迁移率族盒 17(SOX17)基因甲基化与患者病情及预后的关系。方法:收集2022 年6 月至2023 年12 月在本院接受手术切除的152 例PTC患者的甲状腺癌样本和术前血液标本。通过甲基化特异性 PCR(MSP)检测 PTC组织和血浆循环 DNA 中 SOX17 启动子甲基化。结果:MSP 检测结果显示，152 例 PTC 组织中有 71 例SOX17 甲基化(46。7%)，血浆循环DNA中有76 例SOX17 甲基化(50。0%)。Spearman相关分析结果显示，血浆循环DNA中SOX17 甲基化与 PTC 组织中 SOX17 甲基化显著相关(r=0。382，P<0。001)。在PTC组织和血浆循环DNA中，SOX17 甲基化与肿瘤分期Ⅱ～Ⅲ期、肿瘤大小≥2cm、LNM 例数显著相关(P<0。05)。此外，血浆循环DNA中SOX17 甲基化与ETE发生显著相关(P<0。05)。血浆循环DNA中SOX17 甲基化(OR=9。564、2。744，95%CI=3。875～23。602、1。109～6。792)是 PTC 患者发生淋巴结转移(LNM)、甲状腺外侵犯(ETE)的独立影响因素(P<0。05)。血浆循环DNA中SOX17 甲基化在预测LNM和ETE的能力较高，曲线下面积(AUC)为0。731、0。630(灵敏度为74。0%、65。6%，特异度为72。2%、60。4%);PTC组织SOX17 甲基化预测 LNM 和 ETE 的能力较低，曲线下面积(AUC)为 0。604、0。562(灵敏度为57。5%、54。1%，特异度为63。3%、58。2%)。结论:在PTC发生、发展过程中，肿瘤组织及血浆DNA中SOX17 基因启动子甲基化具有高度一致性，并且血浆DNA中SOX17 基因启动子甲基化预测LNM和ETE的能力较高。
Methylation of SOX17 Gene in Plasma Circulating DNA and Its Correlation with Disease Status and Prognosis in Patients with Papillary Thyroid Carcinoma
Objective:To explore the relationship between SOX17 gene methylation in plasma circulating DNA and the disease condition and prognosis of patients with papillary thyroid carcinoma(PTC).Methods:Thyroid cancer tissue and preoperative blood samples were collected from 152 PTC patients who underwent surgical resection between June 2022 and December 2023.Methylation-specific PCR(MSP)was used to de-tect SOX17 promoter methylation in PTC tissues and plasma circulating DNA.Results:MSP results showed that 71 out of 152 PTC tissue samples(46.7%)and 76 plasma circulating DNA samples(50.0%)exhibited SOX17 methylation.Spearman correlation analysis indicated a significant correlation between SOX17 methyla-tion in plasma circulating DNA and PTC tissues(r=0.382,P<0.001).SOX17 methylation in PTC tissue and plasma circulating DNA was significantly associated with tumor stages Ⅱ～Ⅲ,tumor size≥2cm,and lymph node metastasis(LNM)(P<0.05).Furthermore,SOX17 methylation in plasma circulating DNA was significantly related to the occurrence of extrathyroidal extension(ETE)(P<0.05).SOX17 methylation in plasma circulating DNA was identified as an independent factor influencing LNM and ETE in PTC patients(OR=9.564,2.744;95%CI=3.875～23.602,1.109～6.792,P<0.05).The predictive ability of SOX17 methylation in plasma circulating DNA for LNM and ETE was relatively high,with an area under the curve(AUC)of 0.731 and 0.630(sensitivity 74.0%,65.6%;specificity 72.2%,60.4%).In contrast,the pre-dictive ability of SOX17 methylation in PTC tissues for LNM and ETE was lower,with an AUC of 0.604 and 0.562(sensitivity 57.5%,54.1%;specificity 63.3%,58.2%).Conclusion:SOX17 promoter methylation in tumor tissue and plasma DNA exhibits high consistency during the occurrence and progression of PTC.Mo-reover,SOX17 promoter methylation in plasma DNA has a higher predictive value for LNM and ETE.

Papillary thyroid carcinomaSex-determining region Y-box 17PlasmaMethyla-tion-specific PCR

晁祥嵩、孙佳斌、赵长海

展开 >

黑龙江省佳木斯市中心医院乳腺甲状腺外科,黑龙江 佳木斯 154002

乳头状甲状腺癌 Y染色体相关高迁移率族盒17 血浆 甲基化特异性PCR

黑龙江省卫生健康委科研课题

2019-352

2024

10.3969/j.issn.1006-6233.2024.10.021

河北医学
河北省医学会

河北医学

CSTPCD
影响因子：1.915
ISSN：1006-6233
年,卷(期)：2024.30(10)